A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV

Summary

The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.

Eligibility

Age range

18–55 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  VH4011499 low dose Injection

  VH4011499 low dose Injection will be administered subcutaneously and/or intramuscularly.

• Drug
  VH4011499 high dose Injection

  VH4011499 high dose Injection will be administered subcutaneously and/or intramuscularly.

• Drug
  Placebo

  Placebo Injection will be administered either subcutaneously or intramuscularly.

Locations (2)